Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilexs Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a f
June 23, 2025 16:50 ET | Source: Scilex Holding Company PALO ALTO,…
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canadas Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYBs Acute Treatment of Migraine With or Without Aura in Cana
April 15, 2025 09:00 ET | Source: Scilex Holding Company ELYXYB® is…